Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 125 entries
Sorted by: Best Match Show Resources per page
The ReactorSTM: atomically resolved scanning tunneling microscopy under high-pressure, high-temperature catalytic reaction conditions.

The Review of scientific instruments

Herbschleb CT, van der Tuijn PC, Roobol SB, Navarro V, Bakker JW, Liu Q, Stoltz D, Cañas-Ventura ME, Verdoes G, van Spronsen MA, Bergman M, Crama L, Taminiau I, Ofitserov A, van Baarle GJ, Frenken JW.
PMID: 25173272
Rev Sci Instrum. 2014 Aug;85(8):083703. doi: 10.1063/1.4891811.

To enable atomic-scale observations of model catalysts under conditions approaching those used by the chemical industry, we have developed a second generation, high-pressure, high-temperature scanning tunneling microscope (STM): the ReactorSTM. It consists of a compact STM scanner, of which...

Cite
Herbschleb CT, van der Tuijn PC, Roobol SB, et al. The ReactorSTM: atomically resolved scanning tunneling microscopy under high-pressure, high-temperature catalytic reaction conditions. Rev Sci Instrum. 2014;85(8):083703doi: 10.1063/1.4891811.
Herbschleb, C. T., van der Tuijn, P. C., Roobol, S. B., Navarro, V., Bakker, J. W., Liu, Q., Stoltz, D., Cañas-Ventura, M. E., Verdoes, G., van Spronsen, M. A., Bergman, M., Crama, L., Taminiau, I., Ofitserov, A., van Baarle, G. J., & Frenken, J. W. (2014). The ReactorSTM: atomically resolved scanning tunneling microscopy under high-pressure, high-temperature catalytic reaction conditions. The Review of scientific instruments, 85(8), 083703. https://doi.org/10.1063/1.4891811
Herbschleb, C T, et al. "The ReactorSTM: atomically resolved scanning tunneling microscopy under high-pressure, high-temperature catalytic reaction conditions." The Review of scientific instruments vol. 85,8 (2014): 083703. doi: https://doi.org/10.1063/1.4891811
Herbschleb CT, van der Tuijn PC, Roobol SB, Navarro V, Bakker JW, Liu Q, Stoltz D, Cañas-Ventura ME, Verdoes G, van Spronsen MA, Bergman M, Crama L, Taminiau I, Ofitserov A, van Baarle GJ, Frenken JW. The ReactorSTM: atomically resolved scanning tunneling microscopy under high-pressure, high-temperature catalytic reaction conditions. Rev Sci Instrum. 2014 Aug;85(8):083703. doi: 10.1063/1.4891811. PMID: 25173272.
Copy Download .nbib Format: NLM
Improving prediction models with new markers: a comparison of updating strategies.

BMC medical research methodology

Nieboer D, Vergouwe Y, Ankerst DP, Roobol MJ, Steyerberg EW.
PMID: 27678479
BMC Med Res Methodol. 2016 Sep 27;16(1):128. doi: 10.1186/s12874-016-0231-2.

BACKGROUND: New markers hold the promise of improving risk prediction for individual patients. We aimed to compare the performance of different strategies to extend a previously developed prediction model with a new marker.METHODS: Our motivating example was the extension...

Cite
Nieboer D, Vergouwe Y, Ankerst DP, et al. Improving prediction models with new markers: a comparison of updating strategies. BMC Med Res Methodol. 2016;16(1):128doi: 10.1186/s12874-016-0231-2.
Nieboer, D., Vergouwe, Y., Ankerst, D. P., Roobol, M. J., & Steyerberg, E. W. (2016). Improving prediction models with new markers: a comparison of updating strategies. BMC medical research methodology, 16(1), 128. https://doi.org/10.1186/s12874-016-0231-2
Nieboer, D, et al. "Improving prediction models with new markers: a comparison of updating strategies." BMC medical research methodology vol. 16,1 (2016): 128. doi: https://doi.org/10.1186/s12874-016-0231-2
Nieboer D, Vergouwe Y, Ankerst DP, Roobol MJ, Steyerberg EW. Improving prediction models with new markers: a comparison of updating strategies. BMC Med Res Methodol. 2016 Sep 27;16(1):128. doi: 10.1186/s12874-016-0231-2. PMID: 27678479; PMCID: PMC5039804.
Copy Download .nbib Format: NLM
(I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.

European urology

Roobol M.
PMID: 18441533
Eur Urol. 2008 Apr;53(4):852-4; discussion 854-5. doi: 10.1016/j.eururo.2008.01.037.

This study analyses the prostate-specific antigen (PSA) determinations of 11,709 men with two or more PSA measurements within approximately 12 mo, an initial PSA of or 2.5 ng/ml or > or =4.0 ng/ml. The authors found that PSA velocity...

Cite
Roobol M. (I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. Eur Urol. 2008;53(4):852-4; discussion 854-5doi: 10.1016/j.eururo.2008.01.037.
Roobol, M. (2008). (I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. European urology, 53(4), 852-4; discussion 854-5. https://doi.org/10.1016/j.eururo.2008.01.037
Roobol, Monique. "(I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml." European urology vol. 53,4 (2008): 852-4; discussion 854-5. doi: https://doi.org/10.1016/j.eururo.2008.01.037
Roobol M. (I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. Eur Urol. 2008 Apr;53(4):852-4; discussion 854-5. doi: 10.1016/j.eururo.2008.01.037. PMID: 18441533.
Copy Download .nbib Format: NLM
Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic.

Translational andrology and urology

Osses DF, Alberts AR, Bausch GCF, Roobol MJ.
PMID: 29594017
Transl Androl Urol. 2018 Feb;7(1):27-33. doi: 10.21037/tau.2017.12.11.

BACKGROUND: According to their guidelines, Dutch general practitioners (GPs) refer men with prostate-specific antigen (PSA) level ≥3.0 ng/mL to the urologist for risk-based patient selection for prostate biopsy using the Rotterdam Prostate Cancer Risk Calculator (RPCRC). Use of the...

Cite
Osses DF, Alberts AR, Bausch GCF, et al. Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic. Transl Androl Urol. 2018;7(1):27-33doi: 10.21037/tau.2017.12.11.
Osses, D. F., Alberts, A. R., Bausch, G. C. F., & Roobol, M. J. (2018). Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic. Translational andrology and urology, 7(1), 27-33. https://doi.org/10.21037/tau.2017.12.11
Osses, Daniël F, et al. "Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic." Translational andrology and urology vol. 7,1 (2018): 27-33. doi: https://doi.org/10.21037/tau.2017.12.11
Osses DF, Alberts AR, Bausch GCF, Roobol MJ. Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic. Transl Androl Urol. 2018 Feb;7(1):27-33. doi: 10.21037/tau.2017.12.11. PMID: 29594017; PMCID: PMC5861274.
Copy Download .nbib Format: NLM
Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.

Translational andrology and urology

Drost FH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, van der Poel HG, Bangma CH, Roobol MJ.
PMID: 29594024
Transl Androl Urol. 2018 Feb;7(1):98-105. doi: 10.21037/tau.2017.12.28.

BACKGROUND: Active surveillance (AS) for low-risk prostate cancer (PCa) appears to provide excellent long-term PCa-specific and overall survival. The choice for AS as initial treatment is mainly based on avoiding side effects from invasive treatment; but AS entails regular...

Cite
Drost FH, Rannikko A, Valdagni R, et al. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Transl Androl Urol. 2018;7(1):98-105doi: 10.21037/tau.2017.12.28.
Drost, F. H., Rannikko, A., Valdagni, R., Pickles, T., Kakehi, Y., Remmers, S., van der Poel, H. G., Bangma, C. H., Roobol, M. J. (2018). Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Translational andrology and urology, 7(1), 98-105. https://doi.org/10.21037/tau.2017.12.28
Drost, Frank-Jan H, et al. "Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study." Translational andrology and urology vol. 7,1 (2018): 98-105. doi: https://doi.org/10.21037/tau.2017.12.28
Drost FH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, van der Poel HG, Bangma CH, Roobol MJ. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Transl Androl Urol. 2018 Feb;7(1):98-105. doi: 10.21037/tau.2017.12.28. PMID: 29594024; PMCID: PMC5861273.
Copy Download .nbib Format: NLM
From PROMIS to PRO-MRI in primary prostate cancer diagnosis.

Translational andrology and urology

Schoots IG, Roobol MJ.
PMID: 28725608
Transl Androl Urol. 2017 Jun;6(3):604-607. doi: 10.21037/tau.2017.04.35.

No abstract available.

Cite
Schoots IG, Roobol MJ. From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Transl Androl Urol. 2017;6(3):604-607doi: 10.21037/tau.2017.04.35.
Schoots, I. G., & Roobol, M. J. (2017). From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Translational andrology and urology, 6(3), 604-607. https://doi.org/10.21037/tau.2017.04.35
Schoots, Ivo G, and Roobol, Monique J. "From PROMIS to PRO-MRI in primary prostate cancer diagnosis." Translational andrology and urology vol. 6,3 (2017): 604-607. doi: https://doi.org/10.21037/tau.2017.04.35
Schoots IG, Roobol MJ. From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Transl Androl Urol. 2017 Jun;6(3):604-607. doi: 10.21037/tau.2017.04.35. PMID: 28725608; PMCID: PMC5503980.
Copy Download .nbib Format: NLM
Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol.

Central European journal of urology

Sosnowski R, Kamecki H, Daneshmand S, Rudzinski JK, Bjurlin MA, Giganti F, Roobol MJ, Klotz L.
PMID: 32782829
Cent European J Urol. 2020;73(2):123-126. doi: 10.5173/ceju.2020.0167. Epub 2020 Jun 25.

INTRODUCTION: Active surveillance (AS) is a management option recommended by most guidelines for low risk clinically-localized prostate cancer (LR-CLPC). Data shows that AS is being increasingly adopted into clinical practice worldwide. Our aim was to review the up-to date...

Cite
Sosnowski R, Kamecki H, Daneshmand S, et al. Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol. Cent European J Urol. 2020;73(2):123-126doi: 10.5173/ceju.2020.0167.
Sosnowski, R., Kamecki, H., Daneshmand, S., Rudzinski, J. K., Bjurlin, M. A., Giganti, F., Roobol, M. J., & Klotz, L. (2020). Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol. Central European journal of urology, 73(2), 123-126. https://doi.org/10.5173/ceju.2020.0167
Sosnowski, Roman, et al. "Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol." Central European journal of urology vol. 73,2 (2020): 123-126. doi: https://doi.org/10.5173/ceju.2020.0167
Sosnowski R, Kamecki H, Daneshmand S, Rudzinski JK, Bjurlin MA, Giganti F, Roobol MJ, Klotz L. Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol. Cent European J Urol. 2020;73(2):123-126. doi: 10.5173/ceju.2020.0167. Epub 2020 Jun 25. PMID: 32782829; PMCID: PMC7407781.
Copy Download .nbib Format: NLM
Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.

Histopathology

Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG, van Leenders GJLH.
PMID: 34706119
Histopathology. 2021 Oct 27; doi: 10.1111/his.14590. Epub 2021 Oct 27.

AIMS: Gleason pattern 4 (GP4) percentage, invasive cribriform and/or intraductal carcinoma (IC/IDC) and the presence of tertiary Gleason pattern 5 (TP5) in radical prostatectomy (RP) specimens all aid in the risk stratification of Grade Group (GG) 2 prostate cancer...

Cite
Seyrek N, Hollemans E, Osanto S, et al. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. Histopathology. 2021;doi: 10.1111/his.14590.
Seyrek, N., Hollemans, E., Osanto, S., Pelger, R. C. M., van der Poel, H. G., Bekers, E., Bangma, C. H., Rietbergen, J., Roobol, M. J., Schoots, I. G., & van Leenders, G. J. L. H. (2021). Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. Histopathology, . https://doi.org/10.1111/his.14590
Seyrek, Neslisah, et al. "Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients." Histopathology vol. (2021). doi: https://doi.org/10.1111/his.14590
Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG, van Leenders GJLH. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. Histopathology. 2021 Oct 27; doi: 10.1111/his.14590. Epub 2021 Oct 27. PMID: 34706119.
Copy Download .nbib Format: NLM
Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria.

European journal of neurology

Helfferich J, Roodbol J, de Wit MC, Brouwer OF, Jacobs BC.
PMID: 34747551
Eur J Neurol. 2022 Feb;29(2):593-604. doi: 10.1111/ene.15170. Epub 2021 Nov 24.

BACKGROUND AND PURPOSE: Differentiation between acute flaccid myelitis (AFM) and Guillain-Barré syndrome (GBS) can be difficult, particularly in children. Our objective was to improve the diagnostic accuracy by giving recommendations based on a comparison of clinical features and diagnostic...

Cite
Helfferich J, Roodbol J, de Wit MC, et al. Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria. Eur J Neurol. 2021;29(2):593-604doi: 10.1111/ene.15170.
Helfferich, J., Roodbol, J., de Wit, M. C., Brouwer, O. F., Jacobs, B. C. (2022). Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria. European journal of neurology, 29(2), 593-604. https://doi.org/10.1111/ene.15170
Helfferich, Jelte, et al. "Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria." European journal of neurology vol. 29,2 (2022): 593-604. doi: https://doi.org/10.1111/ene.15170
Helfferich J, Roodbol J, de Wit MC, Brouwer OF, Jacobs BC. Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria. Eur J Neurol. 2022 Feb;29(2):593-604. doi: 10.1111/ene.15170. Epub 2021 Nov 24. PMID: 34747551.
Copy Download .nbib Format: NLM
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

HGG advances

Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS.
PMID: 34993496
HGG Adv. 2022 Jan 13;3(1). doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19.

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment....

Cite
Jiang Y, Meyers TJ, Emeka AA, et al. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2021;3(1)doi: 10.1016/j.xhgg.2021.100070.
Jiang, Y., Meyers, T. J., Emeka, A. A., Cooley, L. F., Cooper, P. R., Lancki, N., Helenowski, I., Kachuri, L., Lin, D. W., Stanford, J. L., Newcomb, L. F., Kolb, S., Finelli, A., Fleshner, N. E., Komisarenko, M., Eastham, J. A., Ehdaie, B., Benfante, N., Logothetis, C. J., Gregg, J. R., Perez, C. A., Garza, S., Kim, J., Marks, L. S., Delfin, M., Barsa, D., Vesprini, D., Klotz, L. H., Loblaw, A., Mamedov, A., Goldenberg, S. L., Higano, C. S., Spillane, M., Wu, E., Carter, H. B., Pavlovich, C. P., Mamawala, M., Landis, T., Carroll, P. R., Chan, J. M., Cooperberg, M. R., Cowan, J. E., Morgan, T. M., Siddiqui, J., Martin, R., Klein, E. A., Brittain, K., Gotwald, P., Barocas, D. A., Dallmer, J. R., Gordetsky, J. B., Steele, P., Kundu, S. D., Stockdale, J., Roobol, M. J., Venderbos, L. D. F., Sanda, M. G., Arnold, R., Patil, D., Evans, C. P., Dall'Era, M. A., Vij, A., Costello, A. J., Chow, K., Corcoran, N. M., Rais-Bahrami, S., Phares, C., Scherr, D. S., Flynn, T., Karnes, R. J., Koch, M., Dhondt, C. R., Nelson, J. B., McBride, D., Cookson, M. S., Stratton, K. L., Farriester, S., Hemken, E., Stadler, W. M., Pera, T., Banionyte, D., Bianco, F. J., Lopez, I. H., Loeb, S., Taneja, S. S., Byrne, N., Amling, C. L., Martinez, A., Boileau, L., Gaylis, F. D., Petkewicz, J., Kirwen, N., Helfand, B. T., Xu, J., Scholtens, D. M., Catalona, W. J., & Witte, J. S. (2022). Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG advances, 3(1), . https://doi.org/10.1016/j.xhgg.2021.100070
Jiang, Yu, et al. "Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment." HGG advances vol. 3,1 (2022). doi: https://doi.org/10.1016/j.xhgg.2021.100070
Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13;3(1). doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19. PMID: 34993496; PMCID: PMC8725988.
Copy Download .nbib Format: NLM
Improving Guideline Adherence in Urology.

European urology focus

MacLennan S, Duncan E, Skolarus TA, Roobol MJ, Kasivisvanathan V, Gallagher K, Gandaglia G, Sakalis V, Smith EJ, Plass K, Ribal MJ, N'Dow J, Briganti A.
PMID: 34702647
Eur Urol Focus. 2021 Oct 23; doi: 10.1016/j.euf.2021.10.007. Epub 2021 Oct 23.

CONTEXT: Clinical practice guidelines (CPGs) distil an evidence base into recommendations. CPG adherence is associated with better patient outcomes. However, preparation and dissemination of CPGs are a costly task involving multiple skilled personnel. Furthermore, dissemination alone does not ensure...

Cite
MacLennan S, Duncan E, Skolarus TA, et al. Improving Guideline Adherence in Urology. Eur Urol Focus. 2021;doi: 10.1016/j.euf.2021.10.007.
MacLennan, S., Duncan, E., Skolarus, T. A., Roobol, M. J., Kasivisvanathan, V., Gallagher, K., Gandaglia, G., Sakalis, V., Smith, E. J., Plass, K., Ribal, M. J., N'Dow, J., & Briganti, A. (2021). Improving Guideline Adherence in Urology. European urology focus, . https://doi.org/10.1016/j.euf.2021.10.007
MacLennan, Steven, et al. "Improving Guideline Adherence in Urology." European urology focus vol. (2021). doi: https://doi.org/10.1016/j.euf.2021.10.007
MacLennan S, Duncan E, Skolarus TA, Roobol MJ, Kasivisvanathan V, Gallagher K, Gandaglia G, Sakalis V, Smith EJ, Plass K, Ribal MJ, N'Dow J, Briganti A. Improving Guideline Adherence in Urology. Eur Urol Focus. 2021 Oct 23; doi: 10.1016/j.euf.2021.10.007. Epub 2021 Oct 23. PMID: 34702647.
Copy Download .nbib Format: NLM
Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.

Journal of personalized medicine

Osses DF, Arsov C, Schimmöller L, Schoots IG, van Leenders GJLH, Esposito I, Remmers S, Albers P, Roobol MJ.
PMID: 33321791
J Pers Med. 2020 Dec 10;10(4). doi: 10.3390/jpm10040270.

We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging-Reporting and Data System (PI-RADS) 3...

Cite
Osses DF, Arsov C, Schimmöller L, et al. Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. J Pers Med. 2020;10(4)doi: 10.3390/jpm10040270.
Osses, D. F., Arsov, C., Schimmöller, L., Schoots, I. G., van Leenders, G. J. L. H., Esposito, I., Remmers, S., Albers, P., & Roobol, M. J. (2020). Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. Journal of personalized medicine, 10(4), . https://doi.org/10.3390/jpm10040270
Osses, Daniël F, et al. "Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies." Journal of personalized medicine vol. 10,4 (2020). doi: https://doi.org/10.3390/jpm10040270
Osses DF, Arsov C, Schimmöller L, Schoots IG, van Leenders GJLH, Esposito I, Remmers S, Albers P, Roobol MJ. Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. J Pers Med. 2020 Dec 10;10(4). doi: 10.3390/jpm10040270. PMID: 33321791; PMCID: PMC7768373.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 125 entries